ProCE Banner Activity

CALGB 10603/RATIFY: 10-Yr Follow-up of Midostaurin vs Placebo Combined With Intensive CT for Newly Diagnosed FLT3-Mutant AML 

Conference Coverage
Slideset

In this 10-year follow-up from the RATIFY trial, the addition of midostaurin to intensive chemotherapy in patients 18-59 years of age with FLT3-mutated AML continued to show an EFS benefit but the OS benefit was diminished.

Released: December 10, 2024

Expiration: December 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation